Mirum Pharmaceuticals, Inc. MIRM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $159.88M+7.4% | $148.93M+12.0% | $133.01M+4.1% | $127.79M+14.5% | $111.59M+12.2% | ||
| $97.91M+91.6% | $51.11M+19.0% | $42.96M-6.7% | $46.07M+12.2% | $41.04M-6.8% | ||
| $96.33M+30.0% | $74.13M+19.7% | $61.91M-2.2% | $63.29M+9.7% | $57.71M+1.5% | ||
| $949.35M+518% | $153.5M+17.7% | $130.41M-1.8% | $132.77M+4.7% | $126.77M+2.5% | ||
| $949.35M+518% | $153.5M+17.7% | $130.41M-1.8% | $132.77M+4.7% | $126.77M+2.5% | ||
| -$789.47M-17,186% | -$4.57M-275% | $2.6M+152% | -$4.99M+67.1% | -$15.18M+37.3% | ||
| -493.8%-491pp | -3.1%-5.0pp | 2%+5.9pp | -3.9%+9.7pp | -13.6%+10.8pp | ||
| $3.62M+0.5% | $3.6M-0.2% | $3.61M+0.5% | $3.59M-0.2% | $3.6M+0.5% | ||
| $3.4M-0.6% | $3.42M+5.2% | $3.25M+7.2% | $3.03M+0.3% | $3.02M-5.6% | ||
| $0— | $0-100% | $395K+359% | $86K-95.9% | $2.11M+813% | ||
| -$789.68M-15,811% | -$4.96M-288% | $2.64M+148% | -$5.46M+60.0% | -$13.65M+44.0% | ||
| $475K-38.1% | $767K+393% | -$262K-165% | $402K-60.9% | $1.03M— | ||
| -$790.16M-13,690% | -$5.73M-297% | $2.91M+150% | -$5.86M+60.1% | -$14.68M+38.3% | ||
| -494.2%-490pp | -3.8%-6.0pp | 2.2%+6.8pp | -4.6%+8.6pp | -13.2%+10.8pp | ||
| -$13.43-11,092% | -$0.12-340% | $0.05+142% | -$0.12+60.0% | -$0.30+38.8% | ||
| -$13.43-11,092% | -$0.12-300% | $0.06+150% | -$0.12+60.0% | -$0.30+38.8% | ||
| 58.9M+17.2% | 50.2M-11.9% | 57M+14.6% | 49.7M+1.7% | 48.9M+2.9% | ||
| 58.9M+17.2% | 50.2M-0.9% | 50.6M+1.8% | 49.7M+1.7% | 48.9M+2.9% | ||
| $28.81M+1.9% | $28.26M+10.7% | $25.54M+9.0% | $23.42M+1.8% | $23.02M+1.0% | ||
| $726.3M— | —— | —— | —— | $5M— | ||
| $0— | $0-100% | $395K+359% | $86K-95.9% | $2.11M+813% | ||
| $97.91M+91.6% | $51.11M+19.0% | $42.96M-6.7% | $46.07M+12.2% | $41.04M-6.8% | ||
| $159.88M+7.4% | $148.93M+12.0% | $133.01M+4.1% | $127.79M+14.5% | $111.59M+12.2% | ||
| -$789.47M-17,186% | -$4.57M-275% | $2.6M+152% | -$4.99M+67.1% | -$15.18M+37.3% | ||
| -$782.59M-52,030% | $1.51M-82.6% | $8.67M+712% | $1.07M+112% | -$9.13M+49.7% | ||
| -$782.59M-52,030% | $1.51M-82.6% | $8.67M+712% | $1.07M+112% | -$9.13M+49.7% | ||
| -489.5%-490pp | 1%-5.5pp | 6.5%+5.7pp | 0.8%+9.0pp | -8.2%+10.1pp | ||
| -$789.47M-17,186% | -$4.57M-275% | $2.6M+152% | -$4.99M+67.1% | -$15.18M+37.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s revenue?
- Mirum Pharmaceuticals, Inc. (MIRM) generated $569.6M in revenue over the trailing twelve months, up 50.2% year over year.
- Is Mirum Pharmaceuticals, Inc. profitable?
- Mirum Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $798.8M over the trailing twelve months, a -140.2% net margin.
- What is Mirum Pharmaceuticals, Inc.'s earnings per share?
- Mirum Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-13.62.
- Where does Mirum Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
